Option Care Selected as the Home and Alternate Site Infusion Provider for Newly Approved Breakthrough Therapy, Trogarzo (ibalizumab-uiyk) Injection

By: Option Care
March 9, 2018

BANNOCKBURN, Ill., March 9, 2018 — 全美最大的家庭和备选治疗站点输液服务的独立提供者 Option Care Enterprises, Inc. 被 Theratechnologies Inc. 选定为 Trogarzo^TM (ibalizumab-uiyk) 注射的输液服务提供者，这种静脉 (IV) 输液用于治疗多重耐药性人类免疫缺陷病毒 1 型 (HIV-1) 感染。

除了目前的 HIV 治疗方案外，Option Care 还将为接受 Trogarzo^TM 输液的患者提供个性化的护理管理支持。“通过护理服务、药房管理和患者支持来提高优质的临床价值，使我们能够提供最佳的疗效，”Option Care 业务发展副总裁 Matt Deans 表示。“我们提供无与伦比的家庭和备选治疗站点输液服务的能力使我们能够与创新者合作，将像 Trogarzo^TM 这样的突破性疗法推向市场。此外，提供 Trogarzo^TM 的能力扩大了我们在传染性疾病的输液疗法中的市场领先地位。”

Trogarzo^TM 于 2018 年 3 月获得 FDA 批准，由 Theratechnolgies Inc. 推广和分销。HIV+ 人群中很大一部分人由于治疗的有效性而面临着持续的挑战。Trogarzo^TM 是一种重要的新疗法，它为传统疗法没有疗效且选择有限的患者提供了一项选择。

关于 Option Care

Option Care Enterprises, Inc. (Option Care) is the nation’s largest independent and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.

关于 Trogarzo™ (ibalizumab-uiyk) 注射

Trogarzo™ is a humanized monoclonal antibody for the treatment of multidrug resistant HIV-1 infection. Trogarzo™  binds primarily to the second extracellular domain of the CD4+ T receptor, away from major histocompatibility complex II molecule binding sites. It prevents HIV from infecting CD4+ immune cells while preserving normal immunological function.

关于 Theratechnologies

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy aging and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company’s website at www.theratech.com and on SEDAR at www.sedar.com.

重要的安全信息

Trogarzo™ 是一种搭配其他抗逆转录病毒药物一起使用的处方 HIV 药物，用于治疗成人的人类免疫缺陷病毒-1 (HIV-1) 感染。

Trogarzo™ 阻止 HIV 感染某些细胞的免疫系统。这可以防止 HIV 繁殖，并可减少体内 HIV 的数量。

在您接受 Trogarzo™ 之前，如果您有以下状况，请告知您的医疗保健提供者：

• 怀孕或计划怀孕。Trogarzo™ 对胎儿是否有害尚不清楚。
• 母乳喂养或计划母乳喂养。Trogarzo™ 是否会进入乳汁尚不清楚。

将您服用的所有药物告知您的医疗保健服务提供者，包括所有处方药和非处方药、维生素和草药补充剂。

Trogarzo™ 可能造成严重的副作用，包括：

Changes in your immune  system (Immune Reconstitution Inflammatory Syndrome)  can happen when you start taking HIV-1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time.   Tell your health care provider right away if you start having new symptoms after starting your HIV-1 medicine.

Trogarzo™ 最常见的副作用包括：

• 腹泻
• 晕眩
• 恶心
• 皮疹

如果您出现了困扰您或无法消失的任何副作用，请告知您的医疗保健提供者。这些并非 Trogarzo™ 所有可能产生的副作用。要了解更多信息，请咨询您的医疗保健提供者或药剂师。

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to 1-833-23THERA (1-833-238-4372).

要了解更多信息，包括完整的处方信息和患者信息，请访问 www.trogarzo.com/。